CD4 and cancer: An ideal TAA should display a selective expression in the majority of cancers, and in all phases of tumor progression, in order to be employed in a large number of patients without risk of autoimmune reactions and should have the capacity to elicit strong immune responses ideally involving both CD4+ and CD8+ T lymphocytes [20].